Comparison of 5 day short-course therapies for secondary infection in patients with chronic respiratory disease using gatifloxacin and levofloxacin

Japanese Journal of Chemotherapy

Volumn 55, Issue 6, 2007, Pages 451-462

  Nakamura, Morio ^a   Hasegawa, Naoki ^b   Miyao, Naoki ^c   Nakajima, Takahiro ^d   Terashima, Takeshi ^e   Sakamaki, Fumio ^f   Hiraoka, Rika ^g   Matsubara, Hiroaki ^h   Oyamada, Yoshitaka ⁱ   Yonemaru, Makoto ^j   Nishio, Kazumi ^d   Shimada, Naoto ^d   Kawada, Ichiro ^k   Naoki, Katsuhiko ^l   Tasaka, Sadatomo ^b   Nishimura, Tomoyasu ^b   Ishizaka, Akitoshi ^b  

^a Life Extension Research Institute   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NIPPON KOKAN HOSPITAL   (Japan)

^d KAWASAKI MUNICIPAL HOSPITAL   (Japan)

^e TOKYO DENTAL COLLEGE   (Japan)

^f SAISEIKAI CENTRAL HOSPITAL   (Japan)

^g Saitama Municipal Hospital   (Japan)

^h Fussa Hospital   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^j Isehara Kyodo Hospital   (Japan)

^k Hino Municipal Hospital   (Japan)

^l YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

more..

Author keywords

5 day therapy; Chronic respiratory disease; Gatifloxacin; Levofloxacin; Secondary infection

Indexed keywords

GATIFLOXACIN; LEVOFLOXACIN;

ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC THERAPY; ARTICLE; ASTHMA; BACTERIAL PNEUMONIA; BRONCHIECTASIS; BRONCHIOLITIS; CHRONIC BRONCHITIS; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG EFFICACY; HUMAN; LUNG CANCER; LUNG EMPHYSEMA; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SHORT COURSE THERAPY; STOMACH PAIN; SUPERINFECTION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 37349075257     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Japanese source.
2. Obaji A, Sethi S: Acute exacerbations of chronic bronchitis. Drug and Aging 2001; 18: 1-11
3. Japanese source.
4. Japanese source.
5. Klugman K P: Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990; 3: 171-96
6. Gotfried M H, Deabate C A, Fogarty C, Mathew C P, Sokol W N: Comparison of 5-day, short course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clinical Therapeutics 2001; 23: 97-107
7. Masterton R G, Burley C J, The Study Group: Rndomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. International Journal of Antimicrobial Agents 2001; 18: 503-12
8. Japanese source.
9. Japanese source.
10. Japanese source.
11. Hosaka M, Yasue T, Fukuda H, Tomizawa H, Aoyama H, Hirai K: In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1992; 36: 2108-17
12. Wakabayashi E, Mitsuhashi S: In vivo antibacterial activity of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1994; 38: 594-601
13. Ishida K, Kaku M, Irifune K, Mizukane R, Takemura H, Yoshida R, et al: In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae. J Antimicrob Chemother 1994; 34: 875-83
14. Miyashita N, Niki Y, Kishimoto T, Nakajima M, Matsushima T: In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob Agents Chernother 1997; 41: 1331-4
15. Japanese source.
16. Japanese source.
17. Japanese source.
18. Japanese source.
19. Japanese source.
20. Japanese source.
21. Lister P D: Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. Antimicrob Agents Chemother 2002; 46: 69-74
22. Nightingale C H, Grant EM, Quintiliani R: Pharmacodynamics and Pharmacokinetics of levofloxacin. Chemotherapy 2000; 46: 6-14
23. Jacobs M R: Optimisaton of antimicrobial therapy using pharmacokinetic and pharmacodynamic pharameters. Clin Microbiol Infect 2001; 7: 589-96
24. Saravolatz L, Manzar O, Check C, Pawalak J, Belian B: Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 2001; 47: 875-7
25. Japanese source.
26. Japanese source.
27. Japanese source.
28. Jpn J Clin Pharmacol Ther 2005; 36: 177-80.
29. Japanese source.